ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Dec 06, 2022 12:00 JST
Source: Novotech Health Holdings Pte Ltd
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
SYDNEY, AU, Dec 06, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.
Frost & Sullivan identifies companies that consistently develop growth strategies based on a visionary understanding of the future, and effectively address new challenges and opportunities.
Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."
In response to the Company of the Year Award announcement, Novotech CEO Dr. John Moller said this award is a credit to our entire global team which has decades of biotech drug development experience.
"Every day our team supports biotech companies in their drug development programs with unparalleled regulatory knowledge, vast site and investigator networks, technology-driven clinical data management, and a project management approach focused on problem-solving, ownership, and flexibility. Our global clients benefit from access to our expert teams in Asia Pacific, which is the fastest-growing clinical trial region, due to its vast patient populations and sophisticated medical research infrastructure. Our consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution."
Novotech regularly produces expert reports on East-West strategies. A new publication is now available for international biotechs considering China for their clinical research, as well as China biotechs conducting research in China, and the relevant processes required for global regulatory approvals.
The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech can provide the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.
Download whitepaper here
https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approval
Novotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions delivering exclusive benefits for sponsors.
About Novotech
Novotech is the leading Asia Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit
https://novotech-cro.com/contact
Media Contact
David James
E:
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
NEC Touts "Truly Open, Truly Trusted" Approach to Network Ecosystems for 5G and Beyond at MWC 2023 in Barcelona
Feb 07, 2023 18:06 JST
Mitsubishi Heavy Industries Achieves YoY Increases in Order Intake, Revenue, Business Profit, and Net Income in Third Quarter
Feb 07, 2023 15:38 JST
Renault-Nissan-Mitsubishi Alliance open a new chapter for their partnership
Feb 07, 2023 13:04 JST
KEMRI and NEC Announce Trials on Biometric-based Vaccination Management System for Newborn Children in Kenya
Feb 07, 2023 11:39 JST
Toyota Launches All-New Prius HEV in Japan
Feb 06, 2023 14:39 JST
Fujitsu Launches New Platform to Support Web3 Developers Globally
Feb 06, 2023 13:20 JST
JCB and Vietnam Prosperity Joint Stock Commercial Bank launch VPBank JCB Credit Card with a focus on Generation Z in Viet Nam
Feb 06, 2023 12:00 JST
DENSO Announces Third Quarter Financial Results
Feb 03, 2023 19:24 JST
TOYOTA GAZOO Racing in search of more Swedish snow success
Feb 03, 2023 18:10 JST
Mitsubishi Shipbuilding and INPEX Complete Conceptual Study for Ammonia Bunkering Vessel
Feb 02, 2023 17:03 JST
Fujitsu named to FORTUNE Magazine's 2023 list of "World's Most Admired Companies" for fifth year running
Feb 02, 2023 16:33 JST
Hitachi to Strengthen Business Structure to Accelerate Growth through Digital, Green, and Innovation
Feb 02, 2023 14:19 JST
Fujitsu delivers digital transformation with AI demand forecast service for TORIDOLL noodle shops throughout Japan
Feb 02, 2023 11:36 JST
Compact CO2 Capture System Receives "Awards for Excellence" at the 2022 Nikkei Excellent Products and Services Awards
Feb 01, 2023 16:52 JST
Fujitsu outlines vision for secure and sustainable network technologies at MWC Barcelona 2023
FP
Feb 01, 2023 10:53 JST
Premiere of New Mazda CX-90 Crossover SUV
Feb 01, 2023 09:00 JST
Honda: Production, Sales and Export Results for December, 2022
Jan 31, 2023 11:57 JST
Mazda Production and Sales Results for December 2022 and for January through December 2022
Jan 31, 2023 11:08 JST
DOCOMO Conducts World's First Trial of Transmissive Metasurface on Window to Deliver Indoor Radio Waves to Outdoor Foot of Building
Jan 30, 2023 17:00 JST
Small, Efficient 5G Multisector Antenna Indoor Base Station Achieves World's First Demonstration using 28GHz
Jan 30, 2023 16:35 JST
More Latest Release >>
Related Release
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
February 03 2023 13:00 JST
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
January 12 2023 15:00 JST
Novotech Acquires European CRO, Strengthens Global Operations
January 12 2023 15:00 JST
Novotech is Gold Sponsor at Biotech Showcase 2023
December 20 2022 11:00 JST
Data Shows 50% of New Trials Have Sites in Asia Pacific
December 15 2022 10:00 JST
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
November 11 2022 17:00 JST
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
October 25 2022 18:00 JST
The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval
October 17 2022 11:00 JST
Novotech India Recognised as "Best Workplaces for Women 2022" by Global Work Standards Authority
October 12 2022 09:00 JST
Novotech Selected as Scrip Awards Finalist for Best Full-Service CRO
October 07 2022 10:00 JST
More Press release >>